Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02180048 · ClinicalTrials.gov registry record · NA
"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT02180048: Completed NA study, sponsored by Loma Linda University.
NCT02180048 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02180048, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to observe effects of caffeine on overactive bladder symptoms and wellbeing. This study looks at whether caffeine has bad effects on urinary symptoms or if lower doses of caffeine decrease the effects. The study will propose the following hypothesis: 1. The voiding and mental health symptoms will be greatest in the high dose treatment and lowest in the placebo treatment. 2. The low dose treatment will produce more voiding and mental health symptoms than the placebo treatment. 3. Voiding and mental health symptoms will be mediated by hydration status of the patient which will be assessed using a Tanita Scale.
Primary Outcome
Voiding symptoms will be measured through a composite of self-reported surveys. These surveys are the King's Health Questionnaire, Urinary Distress Inventory, Overactive Bladder Symptom Score, Overactive Bladder Questionnaire.
Interventions
- DIETARY_SUPPLEMENT 400 mg of caffeine/day (Two 200mg pills/day)
- DIETARY_SUPPLEMENT 200 mg of caffeine/day (One 200mg pill and one placebo pill)
- DIETARY_SUPPLEMENT Two placebo pills/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-09-20 |
| Phase | NA |
What the finished NCT02180048 record still lists
NCT02180048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which 400 mg of caffeine/day (Two 200mg pills/day) is the first listed.
NCT02180048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02180048 about?
NCT02180048 is a clinical study titled ""The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"". The purpose of this study is to observe effects of caffeine on overactive bladder symptoms and wellbeing. This study looks at whether caffeine has bad effects on urinary symptoms or if lower doses of caffeine decrease the effects. The study will propose the following hypothesis: 1. The voiding and...
What is the current status of trial NCT02180048?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2014-07. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT02180048?
The interventions under investigation include: 400 mg of caffeine/day (Two 200mg pills/day) (DIETARY_SUPPLEMENT), 200 mg of caffeine/day (One 200mg pill and one placebo pill) (DIETARY_SUPPLEMENT), Two placebo pills/day (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02180048?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02180048's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia